Table 1.
Demographic and clinical characteristics of study subjects
| SLE (n = 53) | RA (n = 52) | HD (n = 23) | |
|---|---|---|---|
| Age (years) | 40.9 ± 17.8 | 64.3 ± 15.7 | 38.1 ± 8.0 |
| Females, n (%) | 49 (92.5) | 35 (67.3) | 20 (87.0) |
| Disease duration (months) | 140.4 ± 159.9 | 83.6 ± 127.1 | |
| SLEDAI score | 4.9 ± 5.4 | ||
| BILAG score | 4.8 ± 6.6 | ||
| Anti-dsDNA (U/ml) | 34.4 ± 82.9 | ||
| IgG (mg/dl) | 1657 ± 710.8 | 1374 ± 396.3 | |
| CH50 (U/ml) | 42.7 ± 14.1 | ||
| C3 (mg/dl) | 84.7 ± 29.2 | ||
| C4 (mg/dl) | 16.7 ± 9.1 | ||
| CRP (mg/dl) | 0.2 ± 0.4 | 1.5 ± 2.0 | |
| ESR (mm/h) | 36.0 ± 31.3 | 42.0 ± 28.1 | |
| Prednisolone use at baseline, n (%) | 36 (67.9) | 18 (34.6) | |
| Dose of prednisolone (mg/day) | 3.1 ± 3.3 | 3.8 ± 9.6 | |
| Hydroxychloroquine use at baseline, n (%) | 30 (56.6) | ||
| Immunosuppressant use at baseline | |||
| Mycophenolate mofetil, n (%) | 10 (18.9) | ||
| Calcineurin inhibitors, n (%) | 9 (17.0) | ||
| Azathioprine, n (%) | 4 (7.5) | ||
| Methotrexate, n (%) | 2 (3.8) | 36 (69.2) | |
| Mizoribine, n (%) | 2 (3.8) | ||
| Leflunomide, n (%) | 1 (1.9) | ||
Data are mean ± SD or percentage of patients
SLEDAI Systemic Lupus Erythematosus Disease Activity Index, BILAG British Isle Lupus Assessment Group, Anti-dsDNA Anti-double-stranded DNA antibody, CRP C-reactive protein, ESR Erythrocyte sedimentation rate